FRANKFURT (Reuters) - German drugmaker Stada (STAGn.DE), at the centre of a takeover battle between two private equity consortia, said fourth-quarter adjusted net income slipped 4 percent, revising lower preliminary unaudited results it posted earlier this month after fully taking into account a smaller acquisition.
Stada, which also makes branded non-prescription treatments and diagnostic kits, said quarterly adjusted net income declined to 37.4 million euros (32.57 million pounds), down from 38.9 million a year earlier.
It had initially reported a figure of 44 million euros.
In its statement on Wednesday, Stada did not comment on the takeover bids. It is due to hold a press conference at 0730 GMT.
The German company confirmed its targets for 2017 and 2019.
Reporting by Ludwig Burger; Editing by Victoria Bryan